A First in Human, Single Ascending Dose Study for the Assessment of Pharmacokinetics, Safety and Tolerability of ABBV-990 in Healthy Male and Female Subjects
Latest Information Update: 02 Nov 2022
At a glance
- Drugs ABBV-990 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 25 Oct 2022 Status changed from recruiting to discontinued.
- 03 Aug 2022 New trial record